The need for treatment and prevention of CAD will increase in the future. This should be recognized especially in the case of risk groups, including patients with a hereditary predisposition to cardiovascular diseases as well as hypertensives, diabetics, obese persons, and smokers. CABG and PTCA improve the patients‘ llRQoL significantly even in the long run